HEXCEL CORP /DE/ (HXL): what the price requires
At today's price, HEXCEL CORP /DE/ (HXL) is priced for today's economics sustained for ~10.3 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.
Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/HXL
Headline
| Field | Value |
|---|---|
| Ticker | HXL |
| Company | HEXCEL CORP /DE/ |
| Current price | $99.26/sh |
| Composition | Composite Materials - Commercial Aerospace 52% / Composite Materials - Defense, Space & Other 28% / Engineered Products - Commercial Aerospace 9% / Engineered Products - Defense, Space & Other 11% |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | whole-company |
| Operating margin needed | 19.3% |
| Operating margin today | 8.8% |
| Margin expansion implied | +10.5pp |
| Must persist for | 10.3y |
| Multiple paid | 43x operating income |
The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.
Solve inputs: computed at a 10% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2 years.
How unusual the bet is: high
| Reference | Value |
|---|---|
| vs own history | +0.07σ |
| cohort percentile (of 76 peers) | 90 |
| sustained it ~10 years at this level | 15% |
| implied end-window share | 0% |
Valuation X-Ray
Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 5.97x | 3 | expensive |
| Earnings | 6.75x | 3 | expensive |
| Relative | 2.62x | 3 | expensive |
| Growth | 1.45x | 3 | expensive |
Families that call it expensive: Asset, Earnings, Relative
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.3%); the inversion above states its own rate.
Per-Model Detail (n=12)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $35.67 | 2.78x | yes | FCF base $0.2B, growth 3% (input: historical growth), terminal g 2.8%, WACC 8.3%, 5yr projection |
| DCF Exit Multiple | Growth | $79.70 | 1.25x | yes | Exit EV/EBITDA: 25.8x / 27.8x / 29.8x (bear / base = today's held flat / bull), 5yr |
| Relative Valuation | Relative | $37.92 | 2.62x | yes | P/S fallback (negative EPS): Sector P/S 1.5x × TTM revenue — excluded from consensus |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $16.59 | 5.98x | yes | BV/sh $16.51, ROE (TTM) 9.3%, ke 9.3% |
| Two-Stage Excess Return | Asset | $16.63 | 5.97x | yes | 5yr excess ROE then converge to ke=9.3% |
| Discounted Future Market Cap | Growth | $68.64 | 1.45x | yes | Rev $1.9B, growth 3% (input: historical growth; tapered), Terminal P/S: 3.3x / 3.9x / 4.6x (bear / base = today's held flat / bull, cap 8x) |
| Peter Lynch Fair Value | Relative | $0.00 | — | no | Negative/zero EPS — earnings-based value floored at $0 |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | $11.02 | 9.01x | yes | Normalized EBIT (5y avg op income, one-time charges added back) $0.18B × (1−18%) / WACC 8.3% → EPV (no growth) |
| Residual Income | Asset | $16.64 | 5.96x | yes | BV $16.51 + 5yr PV of (ROE (TTM) 9.3% − Kₑ 9.3%) × BV; BV grows 6.0%/yr |
| Graham Number | Asset | — | — | no | — |
| EV/EBITDA Relative | Relative | $19.81 | 5.01x | yes | EBITDA $0.31B × sector EV/EBITDA 8.0x |
| FCF Yield | Earnings | $16.67 | 5.95x | yes | FCF $205.6M / Kₑ 9.3% — zero-growth perpetuity |
| SBC-Adj FCF Yield | Earnings | $14.70 | 6.75x | yes | SBC-adj FCF $0.19B (FCF $0.21B − SBC $0.01B) capitalized at Kₑ |
| Ben Graham Formula | Earnings | — | — | no | — |
| ROIC-Justified P/B | Asset | $4.24 | 23.41x | yes | BV $16.51 × (ROIC 2.1% / WACC 8.3%) (excluded from median) |
| P/Sales Sector | Relative | $37.92 | 2.62x | yes | Revenue $1.94B × sector P/S 1.5x |
| PEG Fair Value | Relative | — | — | no | — |
| Earnings Yield | Earnings | — | — | no | — |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net debt | $944.0m |
| Net debt / NOPAT (after-tax) | 6.88x |
| Net debt / operating income (pre-tax) | 5.63x |
| Interest coverage | 4.4x |
| Share count CAGR (buyback) | -2.5% |
| Burning cash | no |
Bullet Takeaways
- Hexcel makes the carbon-fiber and composite materials that go into aircraft wings and fuselages, and roughly 61% of its 2025 sales came from commercial aerospace, which ties its fortunes directly to Boeing and Airbus build rates.
- The defining risk is operating leverage cutting both ways: trailing operating margin is only 9.5% and net debt sits at about five times operating income, so the recovery is real but the balance sheet leaves little room if aircraft production stumbles again.
- Watch the production ramp: commercial-aerospace sales grew 18.8% in the first quarter of 2026 as the 2025 destocking unwound, and continued ramp on the A350, A320, 787, and 737 MAX is what the price is counting on.
Bull Case
Begin with where the price sits relative to what the methods can defend, because it frames everything else. At $97.51, none of the standard valuation lenses reach the price on Hexcel's current earnings. That is not the bull case against itself; it is the bull case stated honestly. Hexcel's trailing numbers reflect a business climbing out of a trough, not a business at steady state. Operating margin is 9.5% today, but the price is built on the expectation that margins return toward the high-teens as volume recovers, and the first quarter of 2026 showed exactly that mechanism beginning to work: net sales rose about 10% to $502 million, and gross margin expanded to 26.9% on higher asset utilization and better price realization on renewed contracts.
The reason to pay forward is the position. Hexcel's lightweight composites are qualified onto specific aircraft programs and stay there for the program's life, the same multi-decade lock-in that defines the best aerospace suppliers. The company's content grows with each newer-generation airframe that uses more composite material per plane. In the first quarter, sales rose across all four major programs, the Airbus A350 and A320 and the Boeing 787 and 737 MAX, and the A350 channel inventory that had weighed on 2025 has largely normalized. That is the operating leverage the bull case rests on: in a fixed-cost manufacturing business, incremental volume drops to the bottom line at a high rate, which is why earnings grew far faster than the 10% sales gain.
Management is running the business as if the recovery is durable. The share count has fallen at about 2.5% a year, direct evidence of buyback deployment rather than dilution, and the company reaffirmed full-year 2026 sales guidance of $2.0 to $2.1 billion. Hexcel sits in an international footprint that is a feature for an aerospace supplier serving two global airframers: 47% of its production and 57% of its customer sales occurred outside the United States in 2025. The bet is that build rates keep climbing and Hexcel's margins climb with them. If they do, today's depressed earnings are the wrong anchor.
Bear Case
The balance sheet is where the recovery story gets uncomfortable. Hexcel carries about $944 million of net debt against trailing operating income of roughly $185 million, which is more than five times operating income, and interest coverage of about 4.4 times is adequate but not generous. That leverage was built for a business earning higher margins than the 9.5% it earns today. As long as the aerospace recovery proceeds, the debt is serviceable. But composites manufacturing is a fixed-cost, capital-heavy business, and fixed costs that magnify profit on the way up magnify pain on the way down. A renewed build-rate cut would compress the volume the whole thesis depends on while the interest bill stays exactly where it is.
That fragility is not hypothetical, because the customer base is concentrated by design. Approximately 61% of Hexcel's 2025 sales came from the commercial-aerospace industry, and the 10-K is direct that "Ongoing pressures on build rates, or reductions in demand, for commercial aircraft or a delay in deliveries could result from many factors". Hexcel does not control its own demand; two airframers and their engine partners do, and 2025 was a live demonstration when A350 destocking pulled sales down and forced the very trough the stock is now recovering from. The lesson of that year is that channel inventory and program timing can swing Hexcel's volume hard in either direction, independent of how well the company executes.
The price has already priced the recovery and then some. To justify $97.51 (June 27, 2026), Hexcel has to roughly double its operating margin toward 19% and hold elevated growth for about a decade. The valuation methods are unanimous that this is a forward bet: the asset-value lens, reading book value and returns, lands near $17 per share; the earnings-power lens, capitalizing current profit with no growth, lands near $11 to $17; peer multiples land near $38. None of the four families reaches the price, which means the price is a bet beyond what any standard frame supports. Return on invested capital is about 2.1%, well below the cost of capital, so today the business is not yet earning its keep on the capital deployed. The bull case requires that to change and stay changed. If the margin recovery stalls at, say, the low teens rather than the high teens, the static methods that say this is a sub-$40 business become the relevant anchor, and the leverage turns a disappointing year into a painful one.
Valuation
What the price is betting is a near-doubling of profitability. At $97.51, the embedded assumption is that Hexcel lifts operating margin toward 19%, from the 9.5% it earns today, and sustains elevated growth for roughly a decade. That is a recovery-plus-durability bet, and it is plausible for a composites supplier riding an aerospace upcycle, but it is demanding: among companies that have sustained that kind of run, only about 15% kept it going for ten years. The priced-in assumption reads as elevated relative to the demonstrated fundamentals, which is unsurprising given that trailing earnings reflect a business just emerging from a destocking trough.
Where the price sits against the methods is the clearest part of the picture, and it is uniform. Every family of method falls short of the price on current earnings. The asset-value methods, reading a book value of $16.51 per share and a return on equity of about 9.3%, land near $17. The earnings-power methods, which capitalize normalized operating profit with no growth, land between roughly $11 and $17. Peer multiples land near $38. The forward-growth models reach highest, the exit-multiple DCF near $78 by holding today's EBITDA multiple flat, but even that does not reach $97.51. The pattern says plainly that the price is a bet on a margin and volume recovery that the trailing numbers do not yet show. The spread between the price and the static lenses is the recovery premium, and it is wide, five to six times on the asset and earnings-power methods.
Solvency is the variable that turns the bet from interesting to risky. Net debt at about five times operating income and interest coverage near 4.4 times are manageable in a recovery and uncomfortable in a downturn. The share count falling at about 2.5% a year shows management returning cash, which is the right signal if the recovery holds. The decisive number for this name is not a valuation output; it is the margin gap, 9.5% earned versus the high-teens the price needs, layered on top of a balance sheet that does not leave much margin for the recovery to disappoint.
Catalysts
Hexcel reported first-quarter 2026 results in late April, and they confirmed the recovery is underway. Net sales rose about 10% to $502 million, with commercial-aerospace sales up 18.8% to $332.7 million as sales increased across all four major programs, the Airbus A350 and A320 and the Boeing 787 and 737 MAX. Gross margin expanded to 26.9% on higher asset utilization, favorable price realization on renewed contracts, and cost discipline. Management noted that channel inventory had largely normalized following the 2025 destocking period, particularly on the A350.
The company held its full-year 2026 sales guidance at $2.0 to $2.1 billion, signaling confidence that the ramp continues but stopping short of raising it amid mixed original-equipment-manufacturer trends. The forward watch items are the Boeing and Airbus production rates, because Hexcel's content scales directly with the number of composite-intensive aircraft built, and the durability of the price realization on renewed contracts. With roughly 61% of sales tied to commercial aerospace, the next several quarterly prints are the place to confirm that the build-rate recovery is sustained rather than another inventory swing, because that trajectory is the entire basis for the premium in the stock.
Peer Cohorts (Per Segment, With Filing Citations)
Composite Materials (reported)
- ATI (ATI INC)
- (no filing in the citation store)
- CRS (CARPENTER TECHNOLOGY CORPORATION)
- (no filing in the citation store)
- MTRN (MATERION CORPORATION)
- (no filing in the citation store)
- HWM (HOWMET AEROSPACE INC.)
- (no filing in the citation store)
- CBT (Cabot Corporation)
- (no filing in the citation store)
Engineered Products (reported)
- HWM (HOWMET AEROSPACE INC.)
- (no filing in the citation store)
- HEI (HEICO CORPORATION)
- (no filing in the citation store)
- TDG (TransDigm Group Incorporated)
- (no filing in the citation store)
- CW (CURTISS-WRIGHT CORPORATION)
- (no filing in the citation store)
- LOAR (Loar Holdings Inc.)
- (no filing in the citation store)
- KRMN (Karman Holdings Inc.)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.
Sources
Hexcel FY2025 10-K, accession 0001193125-26-046377 · Hexcel Q1 2026 earnings release, April 2026 · Hexcel Q1 2026 earnings call, April 2026